Table 1 Baseline patient characteristics
Characteristic | Aliskiren + ARB Group | ARB Group | P value |
|---|---|---|---|
N = 57 | N = 132 | ||
Demographic | |||
Age | 63.9 ± 19.3 | 66.5 ± 15.4 | 0.367 |
Male gender | 61.4% (n = 35) | 68.9% (n = 91) | 0.313 |
Clinical | |||
Body-mass index | 24.8 ± 3.9 | 25.2 ± 3.7 | 0.548 |
Mean sitting blood pressure-mmHg | |||
Systolic | 134.9 ± 16.6 | 131.0 ± 14.0 | 0.123 |
Diastolic | 77.2 ± 10.8 | 77.4 ± 10.5 | 0.135 |
Urine protein-to-creatinine ratio | 1.84 (0.89 ∼ 2.77) | 1.81 (0.84 ∼ 2.78) | 0.723 |
Estimated glomerular filtration rate ml/min/1.73 m2 | 50.9 ± 31.1 | 42.5 ± 19.9 | 0.062 |
Hemoglobin (g/liter) | 12.0 ± 1.9 | 11.8 ± 1.9 | 0.525 |
Chronic kidney disease stage | 0.173 | ||
Stage I | 10.5% (n = 6) | 4.5% (n = 6) | |
Stage II | 17.5% (n = 10) | 7.6% (n = 10) | |
Stage IIIA | 14.0% (n = 8) | 23.5% (n = 31) | |
Stage IIIB | 28.1% (n = 16) | 36.4% (n = 48) | |
Stage IV | 29.8% (n = 17) | 28.0% (n = 37) | |
Etiology | 0.917 | ||
Hypertensive nephropathy | 36.8% (n = 21) | 34.1% (n = 45) | |
Chronic glomerulonephritis | 43.9% (n = 25) | 47.0% (n = 62) | |
Interstitial nephritis | 19.3% (n = 11) | 18.9% (n = 25) | |
Triglycerides (mg/dl) | 146.3 ± 100.2 | 133.0 ± 79.4 | 0.369 |
Cholesterol (mg/dl) | |||
Total | 198.9 ± 52.4 | 183.7 ± 45.7 | 0.062 |
Low-density lipoprotein | 116.4 ± 38.8 | 112.4 ± 37.7 | 0.567 |
High-density lipoprotein | 51.8 ± 14.0 | 48.6 ± 17.3 | 0.309 |
Serum potassium (mmol/liter) | 4.2 ± 0.5 | 4.4 ± 0.6 | 0.037 |
Antihypertensive drugs received at baseline | |||
Calcium-channel blocker | 52.6% (n = 30) | 43.9% (n = 58) | 0.272 |
Beta-blocker | 21.1% (n = 12) | 15.9% (n = 21) | 0.393 |
Diuretic | 35.1% (n = 20) | 47.0% (n = 62) | 0.130 |
Alpha-blocker | 14.0% (n = 8) | 5.3% (n = 7) | 0.042 |